$1.26
0.00% today
Nasdaq, Feb 28, 04:54 pm CET
ISIN
KYG7S53R1049
Symbol
PROK
Sector
Industry

Prokidney Stock price

$1.26
-0.40 23.94% 1M
-0.96 43.21% 6M
-0.44 25.74% YTD
-0.34 21.07% 1Y
-8.63 87.30% 3Y
-8.86 87.59% 5Y
-8.86 87.59% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.05 3.46%
ISIN
KYG7S53R1049
Symbol
PROK
Sector
Industry

Key metrics

Market capitalization $160.60m
Enterprise Value $1.18b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-156.32m
Free Cash Flow (TTM) Free Cash Flow $-133.14m
Cash position $406.81m
EPS (TTM) EPS $-0.56
P/E forward negative
Short interest 10.04%
Show more

Is Prokidney a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Prokidney Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Prokidney forecast:

3x Buy
50%
3x Hold
50%

Analyst Opinions

6 Analysts have issued a Prokidney forecast:

Buy
50%
Hold
50%

Financial data from Prokidney

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 4.03 4.03
22% 22%
-
-4.03 -4.03
22% 22%
-
- Selling and Administrative Expenses 38 38
18% 18%
-
- Research and Development Expense 110 110
5% 5%
-
-152 -152
1% 1%
-
- Depreciation and Amortization 4.03 4.03
22% 22%
-
EBIT (Operating Income) EBIT -156 -156
1% 1%
-
Net Profit -46 -46
26% 26%
-

In millions USD.

Don't miss a Thing! We will send you all news about Prokidney directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prokidney Stock News

Neutral
PRNewsWire
28 days ago
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ProKidney Corp. (NASDAQ: PROK) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Positive
Seeking Alpha
28 days ago
Rilparencel is ProKidney's main candidate. It is intended as a therapy that stabilizes kidneys, making it potentially useful for CKD patients. We'll have Rilparencel's Phase 2 full data in 2025, as well as the potential confirmation about a “surrogate” endpoint for its Phase 3 trials. Currently, Rilparencel's Phase 3 is planned to deliver full data by Q3 2027 if no surrogate endpoint is found t...
Neutral
GlobeNewsWire
3 months ago
WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in December:
More Prokidney News

Company Profile

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease (CKD), shifting the emphasis away from management of kidney failure, to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells (SRCs) prepared from a patient's own, autologous, renal cells. The company is headquartered in Winston-Salem, NC.

Head office Cayman Islands
CEO Bruce Culleton
Employees 163
Founded 2015
Website www.prokidney.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today